TRCT
OTLK icon

Tower Research Capital (TRC)’s Outlook Therapeutics OTLK Stock Holding History

Tower Research Capital (TRC)’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.05K Buy
14,805
+1,932
+15% +$835 ﹤0.01% 4374
2025
Q4 		$20.3K Buy
+12,873
New +$20.6K ﹤0.01% 3086
2025
Q3 		– Sell
-8,259
Closed -$13.2K – 5511
2025
Q2 		$13.2K Sell
8,259
-399
-5% -$636 ﹤0.01% 3870
2025
Q1 		$10.6K Buy
8,658
+2,270
+36% +$3.98K ﹤0.01% 3625
2024
Q4 		$12.1K Buy
6,388
+4,438
+228% +$18.3K ﹤0.01% 3652
2024
Q3 		$10.4K Sell
1,950
-425
-18% -$3.11K ﹤0.01% 3762
2024
Q2 		$17.5K Buy
2,375
+1,865
+366% +$15K ﹤0.01% 3834
2024
Q1 		$6.09K Sell
510
-638
-56% -$5.16K ﹤0.01% 4434
2023
Q4 		$9.04K Sell
1,148
-1,182
-51% -$9.99K ﹤0.01% 4443
2023
Q3 		$10.3K Buy
2,330
+2,099
+909% +$46.4K ﹤0.01% 4127
2023
Q2 		$8.04K Sell
231
-946
-80% -$25.8K ﹤0.01% 4481
2023
Q1 		$26K Buy
1,177
+796
+209% +$17.8K ﹤0.01% 3163
2022
Q4 		$8K Sell
381
-1,724
-82% -$37.5K ﹤0.01% 4434
2022
Q3 		$51K Buy
2,105
+1,298
+161% +$30.2K ﹤0.01% 3141
2022
Q2 		$16K Sell
807
-3,115
-79% -$89.6K ﹤0.01% 4014
2022
Q1 		$139K Buy
3,922
+2,724
+227% +$85.1K ﹤0.01% 1990
2021
Q4 		$33K Buy
1,198
+234
+24% +$8.35K ﹤0.01% 3136
2021
Q3 		$42K Buy
964
+874
+971% +$42.2K ﹤0.01% 3095
2021
Q2 		$4K Sell
90
-1,129
-93% -$52.4K ﹤0.01% 4828
2021
Q1 		$55K Buy
1,219
+881
+261% +$33.7K ﹤0.01% 3047
2020
Q4 		$9K Buy
+338
New +$7.06K ﹤0.01% 4393
2016
Q4 		– Sell
-4
Closed -$3K – 4241
2016
Q3 		$3K Hold
4
– – ﹤0.01% 2873
2016
Q2 		$2K Buy
+4
New +$2.39K ﹤0.01% 3936

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Tower Research Capital (TRC)'s OTLK Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Outlook Therapeutics (OTLK) stake by 15% in Q1 2026, buying an estimated $835 and bringing the position to 14,805 shares worth $3.05K. The position accounts for ﹤0.01% of the portfolio, ranked #4374.

Tower Research Capital (TRC) first reported a position in OTLK in Q2 2016 and has held it in 23 quarters since. The position peaked at $139K in Q1 2022. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • Tower Research Capital (TRC) held 14,805 shares of Outlook Therapeutics worth $3.05K as of Q1 2026.
  • Tower Research Capital (TRC) bought 1,932 Outlook Therapeutics shares in Q1 2026, an estimated $835.
  • Outlook Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4374 holding.
  • Tower Research Capital (TRC) first reported a position in Outlook Therapeutics in Q2 2016 and has held it in 23 quarters since.
  • Tower Research Capital (TRC)'s Outlook Therapeutics position peaked at $139K in Q1 2022.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.